Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.47.

EBIT: As of FY2026 Q2, the actual value is USD -1.148 M.

Segment Revenue

Protagenic Therapeutics, Inc. reported a total revenue of $0 for the three and six months ended September 30, 2025 and 2024, as the company is still in the development stage and has not yet commercialized any product candidates.

Operational Metrics

• Net Loss: The company incurred a net loss of - $869,496 for the three months ended September 30, 2025, compared to - $582,387 for the same period in 2024. For the six months ended September 30, 2025, the net loss was - $5,927,019, compared to - $906,742 for the same period in 2024.
• Operating Expenses: Total operating expenses for the three months ended September 30, 2025 were $1,113,864, compared to $355,374 for the same period in 2024. For the six months ended September 30, 2025, operating expenses were $3,458,276, compared to $677,205 for the same period in 2024.
• Research and Development Expenses: R&D expenses increased significantly to $273,229 for the three months ended September 30, 2025, from $16,964 for the same period in 2024. For the six months ended September 30, 2025, R&D expenses were $667,341, compared to $36,099 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: The company used - $2,562,666 in cash for operating activities during the six months ended September 30, 2025, compared to - $563,868 for the same period in 2024.
• Net Cash Provided by Investing Activities: Cash provided by investing activities was $943,180 for the six months ended September 30, 2025, compared to - $60,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: Financing activities provided $4,407,553 in cash during the six months ended September 30, 2025, compared to $832,833 for the same period in 2024.

Unique Metrics

• Derivative Liabilities: The company recognized a change in the fair value of derivative liabilities related to the conversion option and warrants of $1,930,245 for the six months ended September 30, 2025.

Future Outlook and Strategy

• Core Business Focus: Protagenic Therapeutics plans to continue its ongoing preclinical studies, clinical trials, and product development activities for its pipeline of product candidates. The company aims to seek regulatory approvals for any product candidates that successfully complete clinical trials.
• Non-Core Business: The company has temporarily suspended expenditures related to its preclinical programs and initiated a process to evaluate strategic alternatives for those programs, including partnerships and/or out-licensing, with the objective of advancing them with appropriate external funding while preserving cash for the company’s lead clinical assets.
• Priority: The restructuring plan is expected to reduce annualized operating expenses by approximately $8 million.